Stephen David Prior - 04 Nov 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role: Chief Strategy Officer
Signature: /s/ Lucy Day, Attorney-in-Fact for Stephen David Prior
Issuer symbol: ANTX
Transactions as of: 04 Nov 2025
Net transactions value: -$872
Form type: 4
Filing time: 06 Nov 2025, 18:11:32 UTC
Previous filing: 28 Feb 2025
Next filing: 07 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Prior Stephen David	Chief Strategy Officer	C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK	/s/ Lucy Day, Attorney-in-Fact for Stephen David Prior	06 Nov 2025	0002042268

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANTX	Common Stock	Sale	$872	-765	-1.2%	$1.14	65,548	04 Nov 2025	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2025.
F2	Includes, in accordance with the original terms, (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
F3	Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025.